Global Antibody Partnering Terms and Agreements Entered Into by the World's Leading Healthcare Companies 2010-2016

Mar 17, 2016, 10:10 ET from Research and Markets

DUBLIN, March 17, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" report to their offering.

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies

Report scope

  • Global Antibody Partnering Terms and Agreements 2010 to 2016 includes:
  • Trends in Antibody dealmaking in the biopharma industry since 2010
  • Analysis of Antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Antibody deals
  • Access to over 1,200 Antibody online deal records
  • The leading Antibody deals by value since 2010
  • Most active Antibody dealmakers since 2010
  • The leading Antibody partnering resources

In Global Antibody Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

Chapter 3 - Leading antibody deals

Chapter 4 - Most active antibody dealmakers

Chapter 5 - Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center

For more information visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets